PSG Report Finds Specialty Drug Utilization is Dominant Driver of Trend, Biosimilar Adoption Reshaping the Market

PSG released its 2026 Artemetrx® State of Specialty Spend and Trend Report, noting continued growth in specialty drug spend and identifying claim utilization as the primary driver of trend. The report also says the market is shifting in response to biosimilars. Overall, it is informational industry research with limited immediate implications for specific public equities.

Analysis

The cleanest implication is not a near-term earnings event, but a slow re-pricing of who captures specialty economics: payers/PBMs with specialty pharmacy leverage should take share of the savings pool, while branded biologic owners face a longer glide path of net-price pressure as biosimilar contracts roll. The market often overreads biosimilar headlines as an instant margin reset; in practice, the first 1-2 quarters usually show more mix noise and channel inventory than durable deflation.

The second-order risk is that rising utilization swamps unit-cost savings, which means total spend can keep compounding even as a few headline drugs get cheaper. That is bearish for medical-cost-sensitive health plans if they cannot offset with tighter site-of-care management, but bullish for integrated platforms like UNH/Optum and CVS that monetize steering, distribution, and admin fees. For originator-heavy biotech, the catalyst path is 6-18 months: formulary resets, employer renewals, and payer contracting cycles matter more than the report itself.

Contrarian view: the market may be too early in pricing broad biosimilar substitution. Adoption is usually slower than model sheets assume because rebate walls and physician inertia protect incumbents, so the immediate winners may be overstated. The better trade is relative value, not a blanket short on pharma; the bigger mispricing is likely in names with a visible patent/contracting overhang where biosimilar share can actually convert into lost net revenue on a 2-4 quarter lag.

Key Decisions for Investors

• Prefer UNH and CVS versus XBI/IBB on a 3-6 month relative-value basis; the thesis is that specialty-management scale captures more of the economics than pure biotech does. Falsify if managed-care MLR guidance or pharmacy-services growth deteriorates on the next quarter.
• Use rallies in originator-heavy names with near-term biosimilar exposure, especially REGN, as trimming opportunities over the next 6-12 months. The risk/reward worsens if payers begin giving cleaner formulary wins to biosimilars in the next two contract cycles.
• Accumulate VTRS only on pullbacks as a lagged biosimilar/complex-generic beneficiary; this is a slower, lower-conviction expression, but the upside improves if share data show sustained conversion. Falsify if the company cannot show sequential biosimilar volume growth over the next 2 quarters.
• Do not force an outright trade today in the absence of a fresh pricing catalyst; instead, set an alert for Q2/Q3 payer commentary on specialty trend and biosimilar uptake. If specialty-cost guidance re-accelerates, add to payer/steering winners; if biosimilar substitution stalls, fade the deflation narrative.